AbbVie (ABBV) Cash from Operations (2012 - 2026)

AbbVie (ABBV) has reported Cash from Operations for 15 consecutive years, with $3.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations fell 33.32% year-over-year to $3.4 billion in Q2 2026; TTM through Jun 2026 was $19.5 billion, a 1.16% increase from a year earlier, with the FY2025 full-year figure at $19.0 billion, up 1.19% from the prior year.
• Cash from Operations was $3.4 billion for Q2 2026 at AbbVie, down from $3.8 billion in the prior quarter.
• Over five years, Cash from Operations peaked at $7.6 billion in Q3 2022 and troughed at $1.6 billion in Q1 2025.
• A 5-year average of $5.2 billion and a median of $5.1 billion in 2022 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations slumped 64.06% in 2024 and surged 134.19% in 2026, its largest moves.
• Over 5 years, Cash from Operations stood at $7.4 billion in 2022, then sank by 36.01% to $4.8 billion in 2023, then jumped by 48.29% to $7.0 billion in 2024, then declined by 25.96% to $5.2 billion in 2025, then sank by 34.15% to $3.4 billion in 2026.
• The last three Cash from Operations figures came in at $3.4 billion (Q2 2026), $3.8 billion (Q1 2026), and $5.2 billion (Q4 2025), per Business Quant data.